Related Experiment Video

Updated: Feb 10, 2026

BioMEMS and Cellular Biology: Perspectives and Applications
16:30

BioMEMS and Cellular Biology: Perspectives and Applications

Published on: October 1, 2007

10.2K

Vismodegib and the Hedgehog Pathway Inhibitors: A Historical Perspective to Current Clinical Application

Jennifer C Tang, C William Hanke, Ivor Caro

    Journal of Drugs in Dermatology : JDD
    |May 10, 2018
    PubMed

    Insights

    Vismodegib is a groundbreaking Hedgehog pathway inhibitor for advanced basal cell carcinoma (BCC). Its unique discovery journey highlights the importance of fundamental research in developing novel cancer therapies.

    Area of Science:

    • Oncology
    • Molecular Biology
    • Dermatology

    Background:

    • Basal cell carcinoma (BCC) is the most common human cancer.
    • Advanced BCC often requires novel therapeutic approaches.
    • The Hedgehog signaling pathway is crucial in embryonic development and implicated in BCC pathogenesis.

    Observation:

    • Vismodegib represents the first approved drug targeting the Hedgehog pathway.
    • Its development involved interdisciplinary research, from natural sources to molecular targets.
    • The drug is indicated for metastatic or locally advanced BCC unresponsive to surgery or radiation.

    Findings:

    • Vismodegib's approval marks a significant advancement in BCC treatment.
    • The drug's efficacy in advanced BCC cases has been clinically validated.
    • Its unique origin story underscores the value of diverse scientific exploration.

    Implications:

    • Vismodegib offers a new therapeutic option for patients with difficult-to-treat BCC.
    • The success of Vismodegib may pave the way for other pathway-specific inhibitors.
    • Understanding the Hedgehog pathway's role in cancer opens avenues for future drug discovery.

    More Related Videos

    Fertility Preservation Through Oocyte Vitrification: Clinical and Laboratory Perspectives08:46

    Fertility Preservation Through Oocyte Vitrification: Clinical and Laboratory Perspectives

    Published on: September 16, 2021

    6.7K
    Quantitative PCR-based Assay to Measure Sonic Hedgehog Signaling in Cellular Model of Ciliogenesis07:26

    Quantitative PCR-based Assay to Measure Sonic Hedgehog Signaling in Cellular Model of Ciliogenesis

    Published on: January 31, 2025

    1.1K

    Related Concept Videos

    Hedgehog Signaling Pathway02:33

    Hedgehog Signaling Pathway

    The Hedgehog gene (Hh) was first discovered due to its control of the growth of disorganized, hair-like bristles phenotype in Drosophila, much like hedgehog spines. Hh plays a crucial role in the development of organs and the maintenance of homeostasis in both invertebrates and vertebrates. However, while Drosophila has only one Hh protein, mammals have multiple functional Hedgehog proteins - Sonic (Shh), Desert (Dhh), and Indian Hedgehog (Ihh). All of these homologous proteins have adapted to...
    10.1K
    Changes in Skin Color: Clinical Perspectives01:14

    Changes in Skin Color: Clinical Perspectives

    The first thing a clinician sees is the skin, so the examination of the skin should be part of any thorough physical examination. Most skin disorders are relatively benign, but a few, including melanomas, can be fatal if untreated. A couple of the more noticeable disorders, albinism and vitiligo, affect the appearance of the skin and its accessory organs.
    Albinism
    Albinism is a genetic disorder that affects (completely or partially) the coloring of skin, hair, and eyes. The defect is primarily...
    3.7K
    Clinical Applications of Epidermal Stem Cells01:19

    Clinical Applications of Epidermal Stem Cells

    Epidermal stem cells (EpiSCs) are mainly located at the basal layer of the epidermis. These cells repair minor injuries of the skin and replace dead skin cells. However, EpiSCs’ cannot heal severe wounds such as major burns or those from diabetes or hereditary disorders. In such cases, culturing the epidermal stem cells from the patient is possible and has yielded successful treatment options, such as laboratory-grown skin grafts. These grafts are synthesized using a patient’s own...
    3.3K
    Local Anesthetics: Clinical Application as Spinal Anesthesia01:11

    Local Anesthetics: Clinical Application as Spinal Anesthesia

    Spinal anesthetics are given during lower abdomen and limb surgeries to block sensory and motor neurons. They are administered in the mid to low lumbar regions, primarily acting on the cauda equina's nerve roots. The blockade level depends on the local anesthetic (LA) concentration. Usually, low LA concentrations are sufficient to block sensory fibers, while only high LA concentrations block motor fibers. Other factors like injection volume and speed, the patient's posture, and the drug...
    1.5K
    Local Anesthetics: Clinical Application as Epidural Anesthesia01:29

    Local Anesthetics: Clinical Application as Epidural Anesthesia

    Epidural anesthetics are administered in the fat-filled epidural space, the outermost part of the spinal canal. This technique is commonly employed for pain management and anesthesia during lower abdomen and pelvis surgeries or labor and delivery.
    Since epidural anesthetics can be infused through an epidural catheter, all types of drugs, including short-acting ones, can be administered. Chloroprocaine and lidocaine are examples of short and long-duration anesthetics, respectively. Bupivacaine...
    769
    Eukaryotic Transcription Inhibitors01:52

    Eukaryotic Transcription Inhibitors

    Certain biochemical processes, such as embryonic development and cell growth regulation, depend on the repression of specific genes. DNA binding proteins known as eukaryotic transcription inhibitors regulate the repression of gene expression in eukaryotes. The presence of these inhibitors at the required location and time in the cell is triggered by the presence of hormones and additional signals from other cells.
    Eukaryotic transcription inhibitors usually contain two distinct domains, a...
    11.0K